Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines [Yahoo! Finance]
Inozyme Pharma, Inc. (INZY)
Company Research
Source: Yahoo! Finance
Merger initiates Crossover Financing Round with participation from syndicate members including AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Qiming Venture Partners USA, and Sofinnova Partners Leadership changes: Ophthalmology veteran, Henric Bjarke, joins as CEO LONDON & SEATTLE, December 12, 2024 BUSINESS WIRE )--Tenpoint Therapeutics, Limited ("Tenpoint") and Visus Therapeutics, Inc., ("Visus") announce today the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. The merger brings together a late-stage, potentially best-in-class, presbyopia-correcting eye drop, BRIMOCHOL™ PF, on track for NDA filing in 1H, 2025, with a promising pipeline of innovative therapeutics. The merger unites a strong syndicate of institutional investors who are committed to advancing BRIMOCHOL™ PF through marketing approval to patients worldwide while further advancing Tenpoi
Show less
Read more
Impact Snapshot
Event Time:
INZY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INZY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INZY alerts
High impacting Inozyme Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
INZY
News
- Inozyme Pharma, Inc. (NASDAQ: INZY) is now covered by analysts at Raymond James. They set an "outperform" rating and a $26.00 price target on the stock.MarketBeat
- Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks [Yahoo! Finance]Yahoo! Finance
- Inozyme Pharma to Present at Upcoming Investor ConferencesGlobeNewswire
- Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.MarketBeat
INZY
Earnings
- 11/5/24 - Beat
INZY
Sec Filings
- 12/9/24 - Form SC
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- INZY's page on the SEC website